Backed by 5AM Ventures.
About the role
Entrada Therapeutics is engaging a consultant to provide interim, full-time support to the SEC Reporting & Technical Accounting function from approximately mid-November 2026 through early March 2027. This engagement backfills priority pre-year-end and year-end deliverables while the Associate Director, SEC Reporting temporarily takes on additional responsibilities elsewhere in the accounting organization.
What they're looking for
- BA/BS degree with 7+ years of relevant experience or equivalent
- Prior experience with a top accounting firm and experience gained in a Life Science environment is preferred
- Experience working within a public company reporting structure is required
- Strong proficiency with Microsoft Office related products
- Experience with public company reporting required
- Strong technical accounting experience and research capabilities to properly determine accounting conclusions on key technical matters. Experience with collaboration revenue recognition (ASC606) is strongly preferred
More about this role
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex...
Browse similar: Startup jobs · Boston